Table 2 Univariate analysis for progression free survival in our cohort
Characteristics | Univariate analyses | |
|---|---|---|
HR (95% CI) | P value | |
Age at start of osimertinib, years | ||
  < 60 | 1.00 (Reference) |  |
  ≥ 60 | 0.75 (0.38–1.51) | 0.425 |
Sex | ||
 Female | 1.00 (Reference) |  |
 Male | 1.24 (0.62–2.47) | 0.548 |
Smoker | ||
 Never | 1.00 (Reference) |  |
 Ever | 1.40 (0.64–3.07) | 0.401 |
 Unknown | 1.51 (0.19–11.80) | 0.692 |
Brain metastases | ||
 Yes | 1.00 (Reference) |  |
 None | 0.72 (0.36–1.43) | 0.345 |
Line of therapy | ||
 1st/2nda | 1.00 (Reference) |  |
 3rd or more | 1.05 (0.49–2.24) | 0.900 |
NGS platform | ||
 BGIb | 1.00 (Reference) |  |
 OrigiMed | 1.19 (0.61–2.34) | 0.612 |
EGFR activating mutation | ||
 Exon 19 deletion | 1.00 (Reference) |  |
 Exon 21 L858R | 1.21 (0.57–2.56) | 0.618 |
MSAF | ||
 Lower than the median MSAF | 1.00 (Reference) |  |
 Higher than the median MSAF | 0.73 (0.37–1.45) | 0.373 |
TP53 status | ||
 Mutated | 1.00 (Reference) |  |
 Wild type | 0.53 (0.25–1.11) | 0.092 |
 T790M RMA (continuous) | 0.40 (0.14–1.16) | 0.091 |
 T790M RMP (continuous) | 0.14 (0.04–0.56) | 0.005 |
T790M RMA (categorical) | ||
 ≤ 0.30 | 1.00 (Reference) |  |
 > 0.30 | 0.43 (0.22–0.85) | 0.015 |
T790M RMP (categorical) | ||
 ≤ 0.24 | 1.00 (Reference) |  |
  > 0.24 | 0.36 (0.18–0.72) | 0.004 |